Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04111497 · ClinicalTrials.gov registry record · Phase 1

Glasdegib for Chronic Graft-Versus-Host Disease

A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.

Terminated
Registry status
Phase 1
Development phase
15
Enrollment target

NCT04111497: Clinical Trial Phase 1 study, sponsored by Fred Hutchinson Cancer Center.

NCT04111497 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04111497, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.

TERMINATED
Registry status
Phase 1
Development phase
15 participants
Enrollment target

Study Summary

This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.

Primary Outcome

Safety assessments will consist of monitoring and recording adverse events.

Interventions

  • DRUG Glasdegib

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-12-03
Est. Completion 2023-08-23
Phase Phase 1
Fred Hutchinson Cancer Center

483 total trials

Why NCT04111497 stopped before completion

NCT04111497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).

The record links to 0 conditions, and to 1 intervention - of which Glasdegib is the first listed.

NCT04111497 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04111497 about?

NCT04111497 is a clinical study titled "Glasdegib for Chronic Graft-Versus-Host Disease". This phase I/II trial studies whether glasdegib is helpful in treating sclerosis associated with chronic graft-versus-host disease. It will also investigate the safety of glasdegib in treating patients with chronic graft-versus-host disease.

What is the current status of trial NCT04111497?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-12-03. Estimated completion is 2023-08-23.

What interventions are being tested in trial NCT04111497?

The interventions under investigation include: Glasdegib (DRUG).

Who is sponsoring clinical trial NCT04111497?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04111497's enrollment target sits among peer trials

15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04111497, the US trial registry maintained by the National Library of Medicine. NCT04111497 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.